Solifenacin versus tolterodine— A head-to-head study: Finally! but not final? David R. StaskinRoger R. DmochowskiAlan J. Wein Clinical Trials Report Pages: 403 - 404
The q-t interval and antimuscarinic drugs Roger DmochowskiDavid R. Staskin OriginalPaper Pages: 405 - 409
Overactive bladder in the male patient: epidemiology, etiology, evaluation, and treatment William I. JaffeAlexis E. Te OriginalPaper Pages: 410 - 418
Urologic applications of botox Courtenay MooreRaymond RackleyHoward Goldman OriginalPaper Pages: 419 - 423
Mixed incontinence: The misclassification of patients and limitations of clinical trials Renuka TyagiDavid R. Staskin OriginalPaper Pages: 424 - 428
Efficacy and safety of tadalafil in men with severe erectile dysfunction in tertiary care academic centers Culley C. Carson Clinical Trials Report Pages: 437 - 438
Erectile dysfunction as a marker for vascular disease Kevin L. Billups OriginalPaper Pages: 439 - 444
Lower urinary tract symptoms and erectile dysfunction: Epidemiology and treatment in the aging man Shane RussellKevin T. McVary OriginalPaper Pages: 445 - 453
Conservative management options for peyronie’s disease Gregory S. JackNestor Gonzalez-CadavidJacob Rajfer OriginalPaper Pages: 454 - 460
Erectile dysfunction and treatment of carcinoma of the prostate Culley C. CarsonJ. Slade HubbardEric Wallen OriginalPaper Pages: 461 - 469
Metabolic syndrome, endothelial dysfunction, and erectile dysfunction: Association and management Arthur L. Burnett OriginalPaper Pages: 470 - 475
Hypogonadism in the man with erectile dysfunction: What to look for and when to treat Stephen LazarouAbraham Morgentaler OriginalPaper Pages: 476 - 481
